Key Highlights
- Bruker Corporation expands its preclinical imaging capabilities with the acquisition of Spectral Instruments Imaging LLC.
- The acquisition broadens Bruker’s range of preclinical solutions, including advanced BLI, FLI, and X-ray imaging systems.
- Spectral Instruments Imaging’s flagship systems, such as Lago X and AMI HTX, offer superior sensitivity and versatility for in-vivo research.
Source: Business Wire
Notable Quotes
- “Joining Bruker represents a significant milestone in our history, and we are looking forward to enabling our customers to benefit from different preclinical imaging modalities to understand biological disease processes even more comprehensively in vivo.” – Keith Copeland, CEO at SII
- “We are very pleased to welcome the talented SII team. Their advanced BLI, FLI and X-ray imaging systems complement our portfolio to better serve the diverse needs of our preclinical customers.” – Dr. Wulf-Ingo Jung, President at Bruker’s PCI Division
SoHC's Take
The acquisition of Spectral Instruments Imaging by Bruker Corporation marks a strategic move to enhance their preclinical imaging offerings, further cementing Bruker’s position as a leader in the development of innovative solutions for disease research. By integrating Spectral Instruments Imaging’s advanced optical imaging systems into their portfolio, Bruker is poised to offer unprecedented capabilities in preclinical in-vivo imaging, addressing the complex needs of researchers and advancing the field of disease research. This collaboration underscores the importance of technological innovation and the role of strategic acquisitions in driving forward the capabilities of preclinical research, offering new opportunities for breakthroughs in understanding and treating diseases.
